CN1583069A - Medicine for osteoporosis - Google Patents

Medicine for osteoporosis Download PDF

Info

Publication number
CN1583069A
CN1583069A CN 200410025016 CN200410025016A CN1583069A CN 1583069 A CN1583069 A CN 1583069A CN 200410025016 CN200410025016 CN 200410025016 CN 200410025016 A CN200410025016 A CN 200410025016A CN 1583069 A CN1583069 A CN 1583069A
Authority
CN
China
Prior art keywords
rhizoma
medicine
osteoporosis
treatment
angelicae sinensis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200410025016
Other languages
Chinese (zh)
Other versions
CN1323677C (en
Inventor
陈根生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2004100250164A priority Critical patent/CN1323677C/en
Publication of CN1583069A publication Critical patent/CN1583069A/en
Application granted granted Critical
Publication of CN1323677C publication Critical patent/CN1323677C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

A Chinese medicine for treating osteoporosis is prepared from 9 Chinese-medicinal materials including eucommia bark, Chuan-xiong rhizome, Chinese angelica root, safflower, etc.

Description

The medicine of treatment osteoporosis
Technical field
The present invention relates to medicine, especially a kind of medicine for the treatment of osteoporosis.
Background technology
Bone is a kind of Biocomposite material, constitutes the support of bone by organic gel fibril network structure, and inorganic matter calcium, phosphorus are filled in wherein.Osteoporosis is to be reduced to principal character with general bone amount, osseous tissue microstructure degenerative change, and with sclerotin fragility increases, mechanical strength descends and risk of fractures raises an osteoid metabolic disease.Osteoporosis is divided two classes: a class mainly refers to the female patient in the menopause 15-20, and porous spot accounts for about 70% of this disease sum based on the spongy bone of spinal vertebral and extremities joint portion at this moment; Two classes mainly are meant the masculinity and femininity gerontal patient on 70 years old, and this moment, cortical bone also loosened, and sclerotin becomes fragile, attenuation, and the pulp cavity caliber increases, and accounts for 30% of sum.Women's postmenopausal osteoporosis is meant ovarian function failure, decrease in estrogen, secondary hyperthyroidism, calcitonin hyposecretion, thereby cause bone resorption greater than bone formation, the microstructure degenerative change that occurs with low bone amount and osseous tissue is its feature.Women's postmenopausal osteoporosis patient, about about 6000-7500 ten thousand people of China, about whole world 2.2-2.5 hundred million people, still not having ideal medicine at present treats, main Therapeutic Method has: 1, controversies in hormone replacement in the elderly, need more than the life-time service 7-10, determined curative effect, but severe complications such as the carcinogenic rate of 5-10% and metrorrhagia are arranged; 2, the use of calcium preparation and fluoride preparation can improve the density of bone, but because of not improving the metabolism of bone, increase the fragility of bone on the contrary; 3, the use of phosphate preparation, it can suppress osteoclast activity, but can not promote skeletonization; 4, the use of XIANLING GUBAO, the Chinese medicine preparation of producing by Guizhou celestial miraculous cure industry company limited, state's internal therapy should the most representative Chinese patent medicine of disease at present, the true medicine of curative effect.
Summary of the invention
The medicine of the treatment osteoporosis that purpose of the present invention just provides a kind of determined curative effect, has no side effect, pure Chinese herbal medicine is made.
The pharmaceutical pack of treatment osteoporosis of the present invention contains the following weight parts raw material: Rhizoma Drynariae 8-12, Cortex Eucommiae 4-7, Herba Taxilli 4-7, Rhizoma Cibotii 2-4, Rhizoma Chuanxiong 3-6, Radix Angelicae Sinensis 3-5, Flos Carthami 4-6, Rhizoma Atractylodis Macrocephalae 3-5, Radix Cyathulae 6-10.
The medicine of treatment osteoporosis of the present invention can be prepared into the common drug dosage form by formulation method routinely.
The preparation method of the medicine of treatment osteoporosis of the present invention is: choose raw material by above-mentioned composition, screening, clean, concoct, dry, pulverize, sieve, encapsulated.
The property of medicine of each component raw material in the medicine of treatment osteoporosis of the present invention:
Rhizoma Drynariae: can control the lumbago due to renal deficiency flaccidity of the lower limbs, Hiccough and deaf, chronic diarrhea.Promoting blood circulation and hemostasis is continuous hinders: being applicable to that falling winks frustrates injury of tendon and muscle fracture.
The Cortex Eucommiae: invigorating the liver and kidney, bone and muscle strengthening, antiabortive.Be used for lumbago due to renal deficiency, muscles and bones is unable, blood leaking in gestation, frequent fetal movement; Vascular hypertension.
Herba Taxilli: invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive.Be used for that rheumatic arthralgia, soreness of the waist and knees, muscles and bones are unable, frequent fetal movement, early abortion, vascular hypertension.
Rhizoma Cibotii: invigorating the liver and kidney, remove rheumatism, strong waist foot, sharp joint.Cure mainly lumbago, rheumatism, frequent micturition, seminal emission, leukorrhagia, hemorrhage.
Rhizoma Chuanxiong: blood-activating and qi-promoting, wind-expelling pain-stopping.Be used for menoxenia, amenorrhea dysmenorrhea, abdominal mass stomachache, the twinge of the breast side of body, tumbling and swelling, headache, rheumatic arthralgia.
Radix Angelicae Sinensis: enrich blood and invigorate blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.Be used for blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores Flos Carthami: the latus rectum of invigorating blood circulation, eliminating stasis to stop pain.Be used for that amenorrhea, dysmenorrhea, lochia are not all right, lump in the abdomen mass in the abdomen, traumatic injury.
The Rhizoma Atractylodis Macrocephalae: invigorating the spleen and benefiting QI, the dampness diuretic, hidroschesis is antiabortive.Be used for insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.
Radix Cyathulae: invigorating the liver and kidney, bone and muscle strengthening, eliminating blood stasis and inducing menstruation, conducting blood to flow downwards.Be used for soreness of waist and knee joint, muscles and bones is unable, amenorrhea abdominal mass, dizziness due to hyperactivity of liver-YANG.
The medicine of treatment osteoporosis of the present invention is the theory according to the traditional Chinese medical science " the kidney generating marrow and dominating bone ", based on liver and kidney tonifying, takes into account method of treatment such as spleen invigorating peace stomach, blood circulation promoting and blood stasis dispelling, and selected medicine is formulated.It is monarch drug with the Rhizoma Drynariae, and the Cortex Eucommiae, Herba Taxilli, Rhizoma Cibotii are ministerial drug, and Rhizoma Chuanxiong, Radix Angelicae Sinensis, Flos Carthami are adjuvant drug, and the Rhizoma Atractylodis Macrocephalae, Radix Cyathulae are messenger drug.Compatibility is based on Chinese medicine " organic conception " and " treatment of disease must aim at its pathogenesis " two big rules.
The medicine of treatment osteoporosis of the present invention through clinical practice for many years, shows determined curative effect, from 1996-1999, with self-control Drug therapy women postmenopausal osteoporosis, and establish the matched group contrast, 121 examples are organized in treatment, matched group 118 examples, two groups of cases were 1 course of treatment with 1 month all, and available 1-6 course of treatment, Chinese medicine is decocted in water for oral dose 1 dose of every day, 2 fry in shallow oil 2 each extracting juice 150ml of clothes, gradation clothes.Efficacy assessment standard: (1) produce effects: clinical symptoms all disappears, and recovers the normal activity function, and union of fracture or compression vertebral body partly recover.(2) effective: clinical symptoms is most of to disappear, union of fracture or delayed union, and vertebral body compression nothing increases the weight of, and osteoporosis is improved, and recovers daily routines.(3) invalid: main clinic symptoms, sign, movable function and osteoporosis do not have improvement or increase the weight of.Therapeutic outcome: treatment group produce effects 78 examples, effective 26 examples, invalid 17 examples, total effective rate 86%; Matched group produce effects 41 examples, effective 34 examples, invalid 43 examples, total effective rate 63.3%.Two groups of total effective rates relatively have notable difference (P<0.01), and relatively there were significant differences (P<0.01) for two groups of obvious effective rates.Above case is followed up a case by regular visits to 1-5, and treatment is organized none example refracture is taken place.Wrist fracture, 5 routine compression fracture of lumbar vertebra, 4 routine radius far-end fractures take place in matched group then 2 examples.
The medicine of treatment osteoporosis of the present invention is through China Academy Of Traditional Chinese Medicine Traditional Chinese Medicine Research Institute's animal prerun.Adopt and give 7 weeks of female mice gastric infusion, dosage is in 4g crude drug/kg body weight--16g crude drug/kg body weight, test shows, can make the active significantly reduction of castration mouse phosphatase acid serum, serum inorganic phosphorus content significantly raises, simultaneously can reduce femur length, increase the femur transverse diameter, Chinese medicine preparation " XIANLING GUBAO " the effect similar trend that it is produced the celestial miraculous cure industry of influence and the Guizhou company limited of castration mouse blood biochemical and skeleton.
Show that from experimentatioies clinical and inside and outside two aspects of animal body the medicine of treatment osteoporosis of the present invention can fundamentally be adjusted bone metabolism, make it to transform to normal state balance direction.
The specific embodiment
Embodiment 1:
A kind of pharmaceutical pack for the treatment of osteoporosis contains the following weight parts raw material:
Rhizoma Drynariae 10, the Cortex Eucommiae 5, Herba Taxilli 4, Rhizoma Cibotii 4, Rhizoma Chuanxiong 5, Radix Angelicae Sinensis 4, Flos Carthami 4, the Rhizoma Atractylodis Macrocephalae 3, Radix Cyathulae 8.
Its preparation method is: choose raw material by above-mentioned composition, screening, clean, concoct, dry, pulverize, sieve, encapsulated.
Embodiment 2:
A kind of pharmaceutical pack for the treatment of osteoporosis contains the following weight parts raw material:
Rhizoma Drynariae 8, the Cortex Eucommiae 6, Herba Taxilli 6, Rhizoma Cibotii 2, Rhizoma Chuanxiong 4, Radix Angelicae Sinensis 5, Flos Carthami 6, the Rhizoma Atractylodis Macrocephalae 5, Radix Cyathulae 10.
Its preparation method is identical with embodiment 1.
Embodiment 3:
A kind of pharmaceutical pack for the treatment of osteoporosis contains the following weight parts raw material:
Rhizoma Drynariae 12, the Cortex Eucommiae 4, Herba Taxilli 7, Rhizoma Cibotii 3, Rhizoma Chuanxiong 3, Radix Angelicae Sinensis 4, Flos Carthami 5, the Rhizoma Atractylodis Macrocephalae 4, Radix Cyathulae 6.
Its preparation method is identical with embodiment 1.

Claims (4)

1, a kind of medicine for the treatment of osteoporosis, it is characterized in that: it includes the following weight parts raw material: Rhizoma Drynariae 8-12, Cortex Eucommiae 4-7, Herba Taxilli 4-7, Rhizoma Cibotii 2-4, Rhizoma Chuanxiong 3-6, Radix Angelicae Sinensis 3-5, Flos Carthami 4-6, Rhizoma Atractylodis Macrocephalae 3-5, Radix Cyathulae 6-10.
2, the medicine of treatment osteoporosis according to claim 1 is characterized in that: Rhizoma Drynariae 10, the Cortex Eucommiae 5, Herba Taxilli 4, Rhizoma Cibotii 4, Rhizoma Chuanxiong 5, Radix Angelicae Sinensis 4, Flos Carthami 4, the Rhizoma Atractylodis Macrocephalae 3, Radix Cyathulae 8.
3, the medicine of treatment osteoporosis according to claim 1 is characterized in that: Rhizoma Drynariae 8, the Cortex Eucommiae 6, Herba Taxilli 6, Rhizoma Cibotii 2, Rhizoma Chuanxiong 4, Radix Angelicae Sinensis 5, Flos Carthami 6, the Rhizoma Atractylodis Macrocephalae 5, Radix Cyathulae 10.
4, the medicine of treatment osteoporosis according to claim 1 is characterized in that: Rhizoma Drynariae 12, the Cortex Eucommiae 4, Herba Taxilli 7, Rhizoma Cibotii 3, Rhizoma Chuanxiong 3, Radix Angelicae Sinensis 4, Flos Carthami 5, the Rhizoma Atractylodis Macrocephalae 4, Radix Cyathulae 6.
CNB2004100250164A 2004-06-03 2004-06-03 Medicine for osteoporosis Expired - Fee Related CN1323677C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2004100250164A CN1323677C (en) 2004-06-03 2004-06-03 Medicine for osteoporosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100250164A CN1323677C (en) 2004-06-03 2004-06-03 Medicine for osteoporosis

Publications (2)

Publication Number Publication Date
CN1583069A true CN1583069A (en) 2005-02-23
CN1323677C CN1323677C (en) 2007-07-04

Family

ID=34601102

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100250164A Expired - Fee Related CN1323677C (en) 2004-06-03 2004-06-03 Medicine for osteoporosis

Country Status (1)

Country Link
CN (1) CN1323677C (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101181487B (en) * 2007-11-21 2010-06-23 朱强 Chinese medicine composition orally taken for curing osteosporosis
CN103355660A (en) * 2012-04-11 2013-10-23 北京红墙生物工程有限公司 Healthcare food for improving bone quality and enhancing bone mineral density and preparation method thereof
CN104771634A (en) * 2015-04-22 2015-07-15 赵文健 Medicine for treating coagulated cold vessel impediment type osteoporosis and preparation method thereof
CN105853668A (en) * 2016-05-20 2016-08-17 万宣 Medicament for treating lumbar disc herniation, osteoporosis and cervical spondylosis
CN107837328A (en) * 2017-12-22 2018-03-27 南宁多灵生物科技有限公司 A kind of medicine for treating osteoporosis
CN115006480A (en) * 2022-04-19 2022-09-06 大理大学第一附属医院 Traditional Chinese medicine composition for treating osteoporosis and preparation method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103110762A (en) * 2013-03-23 2013-05-22 汤玮 Traditional Chinese medicine composition for treating old fracture

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1047082C (en) * 1992-05-15 1999-12-08 北京蓉生医药科技发展中心 Process of preparation of medicine tonifying kidney and bone

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101181487B (en) * 2007-11-21 2010-06-23 朱强 Chinese medicine composition orally taken for curing osteosporosis
CN103355660A (en) * 2012-04-11 2013-10-23 北京红墙生物工程有限公司 Healthcare food for improving bone quality and enhancing bone mineral density and preparation method thereof
CN104771634A (en) * 2015-04-22 2015-07-15 赵文健 Medicine for treating coagulated cold vessel impediment type osteoporosis and preparation method thereof
CN105853668A (en) * 2016-05-20 2016-08-17 万宣 Medicament for treating lumbar disc herniation, osteoporosis and cervical spondylosis
CN107837328A (en) * 2017-12-22 2018-03-27 南宁多灵生物科技有限公司 A kind of medicine for treating osteoporosis
CN115006480A (en) * 2022-04-19 2022-09-06 大理大学第一附属医院 Traditional Chinese medicine composition for treating osteoporosis and preparation method thereof
CN115006480B (en) * 2022-04-19 2023-08-22 大理大学第一附属医院 Traditional Chinese medicine composition for treating osteoporosis and preparation method thereof

Also Published As

Publication number Publication date
CN1323677C (en) 2007-07-04

Similar Documents

Publication Publication Date Title
CN102327420B (en) Chinese medicinal composition for setting bones and replenishing muscles and ligaments
CN104147577B (en) A kind of plaster for promoting growth of spur to treat fracture
CN103156972B (en) Traditional Chinese medicine combination for treating fracture, hairline fracture and traumatic injury
CN102872299A (en) Medicine compound for treating osteoporosis and osteoporosis fracture
CN102284028B (en) Medicine for treating rheumatoid arthritis
CN1861187A (en) Medicated wine for treating rheumatosis and osteoarthropathy
CN1907410A (en) Chinese traditional medicine preparation for treating bone fracture and traumatic injury
CN105560662A (en) External-use traditional Chinese medicine composition for treating knee osteoarthritis
CN1294922C (en) Medicine for treating osteoporosis and improving bone fracture healing
CN1323677C (en) Medicine for osteoporosis
CN103263601B (en) Chinese herbal preparation for accelerating fracture post-operation healing and preparation method of Chinese herbal preparation
CN101028506A (en) Chinese-medicinal decoction for treating difficult menstruation
CN103585414B (en) Pharmaceutical composition for treating sciatica and osteoporosis
CN103285203A (en) Traditional Chinese medicine composition for preventing and treating bone fracture and preparation method thereof
CN102836276B (en) Bone spur softening pill for treating osteoarthritis
CN102145099A (en) Traditional Chinese medicine for treating infertility caused by liver stagnation
CN104258077A (en) Traditional Chinese medicine for treating fracture and preparation method thereof
CN1141123C (en) Medicine for threating rheumatism, rheumatoid disease, lumbar intervertebral disk protrusion, hyperosteogeny and ischias and its preparing process
CN103272179B (en) Traditional Chinese medicine, syrup and paste for treating bone fracture and preparation methods thereof
CN103860905A (en) Traditional Chinese medicine preparation for treating osteoporosis
CN105853668A (en) Medicament for treating lumbar disc herniation, osteoporosis and cervical spondylosis
CN102258647B (en) Externally-applied cherokee rose fruit/morinda officinalis/fenugreek powder for treating male impotence
CN1476861A (en) Chinese Medicine preparation for curing female sterility
CN105213793A (en) Cure mainly osteoporotic Chinese medicine composition and method for making
CN1498629A (en) Chinese traditional medicine for treating osteoporosis and its prepn. method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070704